By 2020, demonstrate that the transmission of leprosy and malaria can be interrupted, and the new interventions pioneered by the Novartis Foundation and partners can be integrated into national programs.
Intensify the fight against leprosy by demonstrating the feasibility of an innovative approach toward zero transmission of leprosy in several sites across Asia, Africa and Latin America; and by continuing to provide free multidrug therapy (MDT) to all leprosy patients through WHO by 2020.
By 2017, provide recommendations on developing digital health strategies for the sector, including key publications to give guidance on policy and programmatic implementation when incorporating information communication technology (ICT)/digital health in low and middle-income countries (LMICs)1.
Pioneer “Targeted Parasite Elimination” in Namibia to build the knowledge to shrink the malaria map by 2018.
By 2017, complete one pilot of SMS For Life 2.0 involving at least 300 healthcare facilities and initiate additional pilots in at least two countries in sub-Saharan Africa. Pilots are to deliver training on medicine stock management as well as disease surveillance to healthcare workers via tablet computers.
Launch Novartis Access in 30 countries and reach 20 million patients by the end of 2020.
By 2025, develop and validate at least one innovative healthcare delivery model that addresses the double burden of disease in underserved populations and contributes to the WHO goal of 25% reduction in non-communicable diseases (NCDs) mortality by 2025.
Develop roadmap in Ghana for nationwide scaling of telemedicine project, in expansion phase to reach national scale by 2017 by inclusion in Ghana Health Services.
By 2017, address large burden of hypertension in Ghana to test a community-based model using information communication technology (ICT) to enhance capacity of private sector, Ghana Health Service (GHS) and individuals.
Explore outcomes-based business models for major diseases in at least 10 out of our top 25 markets (3 in 2016, 3 in 2017, 4 in 2018).
Initiate filing submission of approximately 50 local, affordable brands of existing medicines during 2014-2016, and launch approximately 45 affordable original brands of existing medicines in 2015-2017.2
Until 2019, continue to develop key clinical compounds, such as clofazimine to treat drug resistant tuberculosis and make successful compounds available at affordable costs in developing world countries where the diseases are endemic.
Assess safety and efficacy of anti-malarial development compounds KAE609 and KAF156 as treatment and prevention of malaria, considering existing and new combination partners.
Sign collaborative agreements with governments at a Federal / Regional level or with key institutions in key countries in Latin America to drive investment for the respective country and elevate health-related efforts for its citizens in order to position Novartis as trusted/strategic partner. The focus for 2016-2017 is to manage the progress and results of current agreements signed in the region (e.g. Mexico) and explore developing similar initiatives in other countries.
Build alliance called “Pacientes Todos” (We’re all Patients) with other pharmaceutical companies to develop a holistic approach for capacity building for patient advocacy groups (PAGs) in Latin America (through an online platform and local/ regional workshops) in 4 countries by 2017. Capability building includes workshops on sustainability of the organizations & funding, communication strategy, advocacy and ultimately implementing learnings through a key advocacy initiative.